Navigation Links
IPC The Hospitalist Company, Inc. Prices Initial Public Offering
Date:1/25/2008

NORTH HOLLYWOOD, Calif., Jan. 25 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading provider of hospitalist services, announced yesterday the initial public offering of 5,200,000 shares of its common stock at a price to the public of $16.00 per share. The Company has agreed to sell 3,300,000 shares of common stock and the selling stockholders have agreed to sell the remaining 1,900,000 shares of common stock. The selling stockholders have also granted to the underwriters an option for 30 days following the closing to purchase up to an additional 705,000 shares to cover over-allotments, if any.

IPC's common stock will trade on the Nasdaq Global Market under the symbol "IPCM." The offering is expected to close on January 30, 2008, subject to customary closing conditions.

Credit Suisse Securities (USA) LLC and Jefferies & Company, Inc. acted as joint bookrunners for the offering. Wachovia Capital Markets, LLC and William Blair & Company, L.L.C. acted as co-managers for the offering.

This offering is made only by means of a prospectus, copies of which may be obtained from the Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010, (800) 221-1037.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About IPC The Hospitalist Company, Inc.
'/>"/>

SOURCE IPC The Hospitalist Company, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Hospitalist Physicians Help Shorten Patient Stays
2. Benefits of hospitalist care confirmed in new study
3. ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding
4. Nevada company, ORNL develop potential lifesaver
5. Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business
6. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
7. Corporate Benefit Executives Identify Ways to Curb Prescription Drug Prices
8. Albemarle Raises Prices of Specialty Aluminas
9. Albemarle to Raise Prices of Dibromomethane
10. Health care opinion leaders support public reporting of health care quality, prices
11. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
(Date:8/22/2014)... Restore My Vision Today , ... Pearson to help people discover how they can get ... by instead improving their eyesight naturally has caught the ... , “There’s a reason why the glasses and contacts ... because people just assume that it’s their only option ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Testosterone ... filed in U.S. courts on behalf of men ... their use of prescription low testosterone therapies, Bernstein ... new claim was filed against Pfizer Inc. on ... suffered life-threatening heart issues due to his use ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... - Transition Therapeutics Inc. ("Transition" or the "Company") ... the first patient has been dosed in a ... with a proprietary Lilly GLP-1 analogue, in patients ... randomized, double-blind, placebo-controlled study in approximately 140 patients ...
... Kan., March 23 According to the National Bureau ... since December 2007 and nearly half of U.S. residents ... Oprah Winfrey replaced her annual ,Favorite Things, holiday show ... Holiday Ever!"However, the $200 billion health & wellness industry ...
... best news that we have been waiting on for the ... through Sinus Dynamics.WESTLAKE VILLAGE, Calif., March 23 Most ENTs ... if it would be better to have a clinical study ... the sinuses. Now this fantastic news and clinical study proves ...
... an industry leader in transportation brokerage for medical and social ... telephony infrastructure. The upgrade will increase simultaneous call volume capability ... ... Louis, MO (PRWEB) March 23, 2009 - Medical Transportation ...
... quality urgent care, serving local Colorado communities from six immediate care ... ... 2009 -- Urgent care provider NextCare ( www.nextcare.com ) announces the ... new locations in Broomfield and Longmont now open and a location ...
... Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today ... Staphylococcus aureus (MRSA) prevention program that employed ... behavioral change, to trigger significant reductions in MRSA incidence ... In addition, as MRSA rates dropped, the hospitals saw ...
Cached Medicine News:Health News:Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes 2Health News:Consumers Redefine Value in the Recession: Sauna Sales Prove Preventive Health Is an Essential Investment 2Health News:New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:MTM Upgrades its Phone System to Ensure Leading edge Technology and Software Feature sets for Existing and Future Clients 2Health News:Three New NextCare Immediate Care Clinic Locations Open in Colorado 2Health News:CDC analysis finds unique social and behavior intervention helps reduce MRSA rates up to 62 percent 2Health News:CDC analysis finds unique social and behavior intervention helps reduce MRSA rates up to 62 percent 3
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... but,Underscore Need for Improved Patient Communication, Lifestyle,Management ... Elevated,Blood Pressure, NEW YORK, May 19, 2007 ... Harris Interactive(R) for the Hypertension Education,Foundation (HEF) ... Inc. (ASH) Twenty-Second Annual Scientific Meeting,and Exposition ...
... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals ... problem of,hospital-acquired gram-negative pneumonia may have a ... candidate being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results ... the use of,NKTR-061 (Inhaled Amikacin) to treat ...
Cached Medicine Technology:Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 2Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 3Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 4Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 5Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 6Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
... Designed in collaboration with Dr. George ... the Ojemann Cortical Stimulator is the ... procedures. This portable, constant current unit ... settings suitable for use in the ...
... Integra Epilepsy cortical strip electrodes are ... intracranial placement through a burr hole. ... tunneling and enables quick and secure ... Like all Integra Epilepsy electrode designs, ...
...
... URISYS 2400 is designed for laboratories looking ... and convenience in system operation in terms ... and extended calibration and on-board stability., ... system providing enhanced walk-away capability for medium ...
Medicine Products: